nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—F2—systemic lupus erythematosus	0.397	1	CbGaD
Dabigatran etexilate—CES2—Mycophenolate mofetil—systemic lupus erythematosus	0.225	0.498	CbGbCtD
Dabigatran etexilate—CES1—Mycophenolate mofetil—systemic lupus erythematosus	0.0781	0.173	CbGbCtD
Dabigatran etexilate—UGT1A9—Mycophenolate mofetil—systemic lupus erythematosus	0.0474	0.105	CbGbCtD
Dabigatran etexilate—UGT2B7—Mycophenolate mofetil—systemic lupus erythematosus	0.0449	0.0994	CbGbCtD
Dabigatran etexilate—F2—cardial valve—systemic lupus erythematosus	0.0168	0.339	CbGeAlD
Dabigatran etexilate—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.0101	0.0225	CbGbCtD
Dabigatran etexilate—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.00769	0.017	CbGbCtD
Dabigatran etexilate—ABCB1—Betamethasone—systemic lupus erythematosus	0.0066	0.0146	CbGbCtD
Dabigatran etexilate—ABCB1—Prednisolone—systemic lupus erythematosus	0.00651	0.0144	CbGbCtD
Dabigatran etexilate—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.00617	0.0137	CbGbCtD
Dabigatran etexilate—ABCB1—Prednisone—systemic lupus erythematosus	0.00615	0.0136	CbGbCtD
Dabigatran etexilate—ABCB1—Cyclosporine—systemic lupus erythematosus	0.00583	0.0129	CbGbCtD
Dabigatran etexilate—ABCB1—Dexamethasone—systemic lupus erythematosus	0.00384	0.0085	CbGbCtD
Dabigatran etexilate—F2—urine—systemic lupus erythematosus	0.00362	0.0732	CbGeAlD
Dabigatran etexilate—ABCB1—Methotrexate—systemic lupus erythematosus	0.00308	0.00683	CbGbCtD
Dabigatran etexilate—F2—endothelium—systemic lupus erythematosus	0.00212	0.043	CbGeAlD
Dabigatran etexilate—F2—blood plasma—systemic lupus erythematosus	0.00189	0.0382	CbGeAlD
Dabigatran etexilate—UGT1A9—kidney—systemic lupus erythematosus	0.00118	0.0239	CbGeAlD
Dabigatran etexilate—CES2—nephron tubule—systemic lupus erythematosus	0.00108	0.022	CbGeAlD
Dabigatran etexilate—CES2—skin of body—systemic lupus erythematosus	0.00101	0.0205	CbGeAlD
Dabigatran etexilate—F2—connective tissue—systemic lupus erythematosus	0.001	0.0203	CbGeAlD
Dabigatran etexilate—NQO2—nephron tubule—systemic lupus erythematosus	0.000969	0.0196	CbGeAlD
Dabigatran etexilate—UGT2B7—kidney—systemic lupus erythematosus	0.000953	0.0193	CbGeAlD
Dabigatran etexilate—CES2—kidney—systemic lupus erythematosus	0.000953	0.0193	CbGeAlD
Dabigatran etexilate—CES2—cortex of kidney—systemic lupus erythematosus	0.000929	0.0188	CbGeAlD
Dabigatran etexilate—CES1—connective tissue—systemic lupus erythematosus	0.000922	0.0187	CbGeAlD
Dabigatran etexilate—F2—kidney—systemic lupus erythematosus	0.000855	0.0173	CbGeAlD
Dabigatran etexilate—NQO2—kidney—systemic lupus erythematosus	0.000852	0.0172	CbGeAlD
Dabigatran etexilate—NQO2—cortex of kidney—systemic lupus erythematosus	0.00083	0.0168	CbGeAlD
Dabigatran etexilate—CES2—tendon—systemic lupus erythematosus	0.00077	0.0156	CbGeAlD
Dabigatran etexilate—CES2—bone marrow—systemic lupus erythematosus	0.000746	0.0151	CbGeAlD
Dabigatran etexilate—F2—lymphoid tissue—systemic lupus erythematosus	0.000734	0.0149	CbGeAlD
Dabigatran etexilate—NQO2—tendon—systemic lupus erythematosus	0.000688	0.0139	CbGeAlD
Dabigatran etexilate—CES2—lung—systemic lupus erythematosus	0.000676	0.0137	CbGeAlD
Dabigatran etexilate—CES1—lymphoid tissue—systemic lupus erythematosus	0.000674	0.0136	CbGeAlD
Dabigatran etexilate—F2—bone marrow—systemic lupus erythematosus	0.000669	0.0135	CbGeAlD
Dabigatran etexilate—NQO2—bone marrow—systemic lupus erythematosus	0.000666	0.0135	CbGeAlD
Dabigatran etexilate—CES2—nervous system—systemic lupus erythematosus	0.000626	0.0127	CbGeAlD
Dabigatran etexilate—F2—lung—systemic lupus erythematosus	0.000606	0.0123	CbGeAlD
Dabigatran etexilate—NQO2—lung—systemic lupus erythematosus	0.000604	0.0122	CbGeAlD
Dabigatran etexilate—CES2—central nervous system—systemic lupus erythematosus	0.000602	0.0122	CbGeAlD
Dabigatran etexilate—F2—nervous system—systemic lupus erythematosus	0.000561	0.0114	CbGeAlD
Dabigatran etexilate—NQO2—nervous system—systemic lupus erythematosus	0.000559	0.0113	CbGeAlD
Dabigatran etexilate—CES1—lung—systemic lupus erythematosus	0.000556	0.0113	CbGeAlD
Dabigatran etexilate—F2—central nervous system—systemic lupus erythematosus	0.00054	0.0109	CbGeAlD
Dabigatran etexilate—NQO2—central nervous system—systemic lupus erythematosus	0.000538	0.0109	CbGeAlD
Dabigatran etexilate—CES1—nervous system—systemic lupus erythematosus	0.000515	0.0104	CbGeAlD
Dabigatran etexilate—CES1—central nervous system—systemic lupus erythematosus	0.000496	0.01	CbGeAlD
Dabigatran etexilate—ABCB1—blood plasma—systemic lupus erythematosus	0.000406	0.00821	CbGeAlD
Dabigatran etexilate—ABCB1—nephron tubule—systemic lupus erythematosus	0.000209	0.00424	CbGeAlD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—SELE—systemic lupus erythematosus	0.000191	0.00749	CbGpPWpGaD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—NR3C1—systemic lupus erythematosus	0.000187	0.00735	CbGpPWpGaD
Dabigatran etexilate—ABCB1—kidney—systemic lupus erythematosus	0.000184	0.00372	CbGeAlD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN1A—systemic lupus erythematosus	0.000183	0.00719	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—ITGAM—systemic lupus erythematosus	0.000179	0.00704	CbGpPWpGaD
Dabigatran etexilate—ABCB1—cortex of kidney—systemic lupus erythematosus	0.000179	0.00363	CbGeAlD
Dabigatran etexilate—UGT1A9—Phase II conjugation—NAT2—systemic lupus erythematosus	0.000178	0.007	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—EP300—systemic lupus erythematosus	0.000174	0.00684	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—LYN—systemic lupus erythematosus	0.000173	0.00681	CbGpPWpGaD
Dabigatran etexilate—F2—IL1 and megakaryotyces in obesity—MMP9—systemic lupus erythematosus	0.000162	0.00638	CbGpPWpGaD
Dabigatran etexilate—ABCB1—lymphoid tissue—systemic lupus erythematosus	0.000158	0.0032	CbGeAlD
Dabigatran etexilate—UGT2B15—Biological oxidations—RXRA—systemic lupus erythematosus	0.000158	0.0062	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Drug Induction of Bile Acid Pathway—VDR—systemic lupus erythematosus	0.000154	0.00607	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—CRP—systemic lupus erythematosus	0.000151	0.00593	CbGpPWpGaD
Dabigatran etexilate—ABCB1—bone marrow—systemic lupus erythematosus	0.000144	0.00291	CbGeAlD
Dabigatran etexilate—CES1—NRF2 pathway—RXRA—systemic lupus erythematosus	0.000143	0.00561	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL4—systemic lupus erythematosus	0.000142	0.00559	CbGpPWpGaD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—C3—systemic lupus erythematosus	0.000141	0.00555	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—CSK—systemic lupus erythematosus	0.000137	0.0054	CbGpPWpGaD
Dabigatran etexilate—ABCB1—lung—systemic lupus erythematosus	0.00013	0.00264	CbGeAlD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—ALB—systemic lupus erythematosus	0.00013	0.00512	CbGpPWpGaD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—MMP9—systemic lupus erythematosus	0.000129	0.00507	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Biological oxidations—NAT2—systemic lupus erythematosus	0.000128	0.00504	CbGpPWpGaD
Dabigatran etexilate—F2—PAR1-mediated thrombin signaling events—NOS3—systemic lupus erythematosus	0.000127	0.00499	CbGpPWpGaD
Dabigatran etexilate—F2—Post-translational protein modification—MAN2A1—systemic lupus erythematosus	0.000127	0.00499	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—NAT2—systemic lupus erythematosus	0.000126	0.00497	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—CCL2—systemic lupus erythematosus	0.000124	0.00488	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—CRP—systemic lupus erythematosus	0.000123	0.00483	CbGpPWpGaD
Dabigatran etexilate—ABCB1—nervous system—systemic lupus erythematosus	0.000121	0.00244	CbGeAlD
Dabigatran etexilate—ABCB1—Allograft Rejection—C4A—systemic lupus erythematosus	0.000117	0.00462	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN1B—systemic lupus erythematosus	0.000117	0.00459	CbGpPWpGaD
Dabigatran etexilate—ABCB1—central nervous system—systemic lupus erythematosus	0.000116	0.00235	CbGeAlD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—ALB—systemic lupus erythematosus	0.000116	0.00455	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—CLU—systemic lupus erythematosus	0.000112	0.00442	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic lupus erythematosus	0.000112	0.00442	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—P2RY12—systemic lupus erythematosus	0.000109	0.00428	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN1A—systemic lupus erythematosus	0.000108	0.00424	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—LYN—systemic lupus erythematosus	0.000106	0.00415	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IFNG—systemic lupus erythematosus	0.000106	0.00415	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—NAT2—systemic lupus erythematosus	0.000104	0.00409	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000103	0.00404	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—NAT2—systemic lupus erythematosus	0.000103	0.00404	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—EP300—systemic lupus erythematosus	0.000103	0.00403	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—CCL2—systemic lupus erythematosus	0.000101	0.00397	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—CSK—systemic lupus erythematosus	0.0001	0.00394	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—CRP—systemic lupus erythematosus	9.75e-05	0.00384	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—ALB—systemic lupus erythematosus	9.41e-05	0.0037	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—LYN—systemic lupus erythematosus	9.11e-05	0.00358	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—systemic lupus erythematosus	8.98e-05	0.00353	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Cyclosporine—systemic lupus erythematosus	8.95e-05	0.00117	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Mycophenolate mofetil—systemic lupus erythematosus	8.92e-05	0.00116	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Hydrocortisone—systemic lupus erythematosus	8.92e-05	0.00116	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Leflunomide—systemic lupus erythematosus	8.9e-05	0.00116	CcSEcCtD
Dabigatran etexilate—Hypertension—Triamcinolone—systemic lupus erythematosus	8.89e-05	0.00116	CcSEcCtD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	8.87e-05	0.00349	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Methylprednisolone—systemic lupus erythematosus	8.87e-05	0.00116	CcSEcCtD
Dabigatran etexilate—Infection—Hydrocortisone—systemic lupus erythematosus	8.87e-05	0.00116	CcSEcCtD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—systemic lupus erythematosus	8.85e-05	0.00348	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Cyclosporine—systemic lupus erythematosus	8.84e-05	0.00115	CcSEcCtD
Dabigatran etexilate—Shock—Hydrocortisone—systemic lupus erythematosus	8.78e-05	0.00114	CcSEcCtD
Dabigatran etexilate—Vomiting—Azathioprine—systemic lupus erythematosus	8.76e-05	0.00114	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Hydrocortisone—systemic lupus erythematosus	8.75e-05	0.00114	CcSEcCtD
Dabigatran etexilate—Pneumonia—Methotrexate—systemic lupus erythematosus	8.75e-05	0.00114	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methylprednisolone—systemic lupus erythematosus	8.75e-05	0.00114	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Mycophenolate mofetil—systemic lupus erythematosus	8.73e-05	0.00114	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Methotrexate—systemic lupus erythematosus	8.7e-05	0.00113	CcSEcCtD
Dabigatran etexilate—Infestation—Methotrexate—systemic lupus erythematosus	8.7e-05	0.00113	CcSEcCtD
Dabigatran etexilate—CES2—NRF2 pathway—TGFB1—systemic lupus erythematosus	8.69e-05	0.00342	CbGpPWpGaD
Dabigatran etexilate—Rash—Azathioprine—systemic lupus erythematosus	8.69e-05	0.00113	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—systemic lupus erythematosus	8.69e-05	0.00113	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	8.69e-05	0.00342	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Azathioprine—systemic lupus erythematosus	8.68e-05	0.00113	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Cyclosporine—systemic lupus erythematosus	8.67e-05	0.00113	CcSEcCtD
Dabigatran etexilate—Skin disorder—Hydrocortisone—systemic lupus erythematosus	8.67e-05	0.00113	CcSEcCtD
Dabigatran etexilate—Fatigue—Cyclosporine—systemic lupus erythematosus	8.66e-05	0.00113	CcSEcCtD
Dabigatran etexilate—Headache—Azathioprine—systemic lupus erythematosus	8.63e-05	0.00112	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Mycophenolate mofetil—systemic lupus erythematosus	8.62e-05	0.00112	CcSEcCtD
Dabigatran etexilate—Dizziness—Leflunomide—systemic lupus erythematosus	8.6e-05	0.00112	CcSEcCtD
Dabigatran etexilate—Constipation—Cyclosporine—systemic lupus erythematosus	8.59e-05	0.00112	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—IFNG—systemic lupus erythematosus	8.59e-05	0.00338	CbGpPWpGaD
Dabigatran etexilate—Angioedema—Dexamethasone—systemic lupus erythematosus	8.54e-05	0.00111	CcSEcCtD
Dabigatran etexilate—Angioedema—Betamethasone—systemic lupus erythematosus	8.54e-05	0.00111	CcSEcCtD
Dabigatran etexilate—Angiopathy—Prednisone—systemic lupus erythematosus	8.48e-05	0.0011	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Mycophenolate mofetil—systemic lupus erythematosus	8.46e-05	0.0011	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Prednisone—systemic lupus erythematosus	8.44e-05	0.0011	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Triamcinolone—systemic lupus erythematosus	8.4e-05	0.0011	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methylprednisolone—systemic lupus erythematosus	8.38e-05	0.00109	CcSEcCtD
Dabigatran etexilate—Syncope—Dexamethasone—systemic lupus erythematosus	8.38e-05	0.00109	CcSEcCtD
Dabigatran etexilate—Syncope—Betamethasone—systemic lupus erythematosus	8.38e-05	0.00109	CcSEcCtD
Dabigatran etexilate—Constipation—Mycophenolate mofetil—systemic lupus erythematosus	8.38e-05	0.00109	CcSEcCtD
Dabigatran etexilate—Infection—Triamcinolone—systemic lupus erythematosus	8.35e-05	0.00109	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—RXRA—systemic lupus erythematosus	8.35e-05	0.00328	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Hydrocortisone—systemic lupus erythematosus	8.34e-05	0.00109	CcSEcCtD
Dabigatran etexilate—Infection—Methylprednisolone—systemic lupus erythematosus	8.33e-05	0.00109	CcSEcCtD
Dabigatran etexilate—Haematuria—Methotrexate—systemic lupus erythematosus	8.3e-05	0.00108	CcSEcCtD
Dabigatran etexilate—Vomiting—Leflunomide—systemic lupus erythematosus	8.27e-05	0.00108	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCL12—systemic lupus erythematosus	8.27e-05	0.00325	CbGpPWpGaD
Dabigatran etexilate—Shock—Triamcinolone—systemic lupus erythematosus	8.27e-05	0.00108	CcSEcCtD
Dabigatran etexilate—Shock—Methylprednisolone—systemic lupus erythematosus	8.25e-05	0.00107	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—P2RY12—systemic lupus erythematosus	8.24e-05	0.00324	CbGpPWpGaD
Dabigatran etexilate—Hepatobiliary disease—Methotrexate—systemic lupus erythematosus	8.23e-05	0.00107	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methylprednisolone—systemic lupus erythematosus	8.22e-05	0.00107	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—FOXP3—systemic lupus erythematosus	8.22e-05	0.00323	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Cyclosporine—systemic lupus erythematosus	8.21e-05	0.00107	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Betamethasone—systemic lupus erythematosus	8.21e-05	0.00107	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Dexamethasone—systemic lupus erythematosus	8.21e-05	0.00107	CcSEcCtD
Dabigatran etexilate—Epistaxis—Methotrexate—systemic lupus erythematosus	8.21e-05	0.00107	CcSEcCtD
Dabigatran etexilate—Rash—Leflunomide—systemic lupus erythematosus	8.2e-05	0.00107	CcSEcCtD
Dabigatran etexilate—Dermatitis—Leflunomide—systemic lupus erythematosus	8.2e-05	0.00107	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—RXRA—systemic lupus erythematosus	8.19e-05	0.00322	CbGpPWpGaD
Dabigatran etexilate—Nausea—Azathioprine—systemic lupus erythematosus	8.18e-05	0.00107	CcSEcCtD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—systemic lupus erythematosus	8.17e-05	0.00321	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—ETS1—systemic lupus erythematosus	8.17e-05	0.00321	CbGpPWpGaD
Dabigatran etexilate—Headache—Leflunomide—systemic lupus erythematosus	8.15e-05	0.00106	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methylprednisolone—systemic lupus erythematosus	8.14e-05	0.00106	CcSEcCtD
Dabigatran etexilate—Malnutrition—Prednisone—systemic lupus erythematosus	8.14e-05	0.00106	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Hydrocortisone—systemic lupus erythematosus	8.13e-05	0.00106	CcSEcCtD
Dabigatran etexilate—Hypertension—Dexamethasone—systemic lupus erythematosus	8.07e-05	0.00105	CcSEcCtD
Dabigatran etexilate—Hypertension—Betamethasone—systemic lupus erythematosus	8.07e-05	0.00105	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—CCL2—systemic lupus erythematosus	8.02e-05	0.00315	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Mycophenolate mofetil—systemic lupus erythematosus	8.01e-05	0.00104	CcSEcCtD
Dabigatran etexilate—Urticaria—Cyclosporine—systemic lupus erythematosus	7.98e-05	0.00104	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Cyclosporine—systemic lupus erythematosus	7.94e-05	0.00103	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	7.89e-05	0.0031	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Hydrocortisone—systemic lupus erythematosus	7.86e-05	0.00102	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Methotrexate—systemic lupus erythematosus	7.85e-05	0.00102	CcSEcCtD
Dabigatran etexilate—Hypotension—Methylprednisolone—systemic lupus erythematosus	7.83e-05	0.00102	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Methotrexate—systemic lupus erythematosus	7.81e-05	0.00102	CcSEcCtD
Dabigatran etexilate—F2—G alpha (q) signalling events—RASGRP1—systemic lupus erythematosus	7.81e-05	0.00307	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Mycophenolate mofetil—systemic lupus erythematosus	7.78e-05	0.00101	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Mycophenolate mofetil—systemic lupus erythematosus	7.74e-05	0.00101	CcSEcCtD
Dabigatran etexilate—Nausea—Leflunomide—systemic lupus erythematosus	7.73e-05	0.00101	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	7.72e-05	0.00304	CbGpPWpGaD
Dabigatran etexilate—Urinary tract disorder—Methotrexate—systemic lupus erythematosus	7.71e-05	0.00101	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Hydrocortisone—systemic lupus erythematosus	7.7e-05	0.001	CcSEcCtD
Dabigatran etexilate—Fatigue—Hydrocortisone—systemic lupus erythematosus	7.69e-05	0.001	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Methotrexate—systemic lupus erythematosus	7.66e-05	0.000998	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	7.66e-05	0.000998	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	7.64e-05	0.000995	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—IL2—systemic lupus erythematosus	7.63e-05	0.003	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Dexamethasone—systemic lupus erythematosus	7.62e-05	0.000994	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Betamethasone—systemic lupus erythematosus	7.62e-05	0.000994	CcSEcCtD
Dabigatran etexilate—Infection—Betamethasone—systemic lupus erythematosus	7.57e-05	0.000987	CcSEcCtD
Dabigatran etexilate—Infection—Dexamethasone—systemic lupus erythematosus	7.57e-05	0.000987	CcSEcCtD
Dabigatran etexilate—Anaemia—Prednisone—systemic lupus erythematosus	7.52e-05	0.00098	CcSEcCtD
Dabigatran etexilate—Shock—Betamethasone—systemic lupus erythematosus	7.5e-05	0.000978	CcSEcCtD
Dabigatran etexilate—Shock—Dexamethasone—systemic lupus erythematosus	7.5e-05	0.000978	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Triamcinolone—systemic lupus erythematosus	7.49e-05	0.000976	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	7.48e-05	0.000974	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Betamethasone—systemic lupus erythematosus	7.48e-05	0.000974	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—ALB—systemic lupus erythematosus	7.48e-05	0.00294	CbGpPWpGaD
Dabigatran etexilate—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	7.47e-05	0.000973	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	7.47e-05	0.000973	CcSEcCtD
Dabigatran etexilate—Angioedema—Prednisone—systemic lupus erythematosus	7.43e-05	0.000969	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	7.4e-05	0.000964	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Triamcinolone—systemic lupus erythematosus	7.4e-05	0.000964	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	7.38e-05	0.000962	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	7.3e-05	0.000951	CcSEcCtD
Dabigatran etexilate—Syncope—Prednisone—systemic lupus erythematosus	7.3e-05	0.000951	CcSEcCtD
Dabigatran etexilate—Urticaria—Prednisolone—systemic lupus erythematosus	7.26e-05	0.000946	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—systemic lupus erythematosus	7.25e-05	0.000945	CcSEcCtD
Dabigatran etexilate—Fatigue—Triamcinolone—systemic lupus erythematosus	7.24e-05	0.000944	CcSEcCtD
Dabigatran etexilate—Fatigue—Methylprednisolone—systemic lupus erythematosus	7.23e-05	0.000942	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	7.22e-05	0.00094	CcSEcCtD
Dabigatran etexilate—Asthenia—Cyclosporine—systemic lupus erythematosus	7.2e-05	0.000939	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—RXRA—systemic lupus erythematosus	7.18e-05	0.00282	CbGpPWpGaD
Dabigatran etexilate—Loss of consciousness—Prednisone—systemic lupus erythematosus	7.15e-05	0.000932	CcSEcCtD
Dabigatran etexilate—Hypotension—Betamethasone—systemic lupus erythematosus	7.12e-05	0.000928	CcSEcCtD
Dabigatran etexilate—Hypotension—Dexamethasone—systemic lupus erythematosus	7.12e-05	0.000928	CcSEcCtD
Dabigatran etexilate—Pruritus—Cyclosporine—systemic lupus erythematosus	7.1e-05	0.000926	CcSEcCtD
Dabigatran etexilate—Urticaria—Hydrocortisone—systemic lupus erythematosus	7.09e-05	0.000924	CcSEcCtD
Dabigatran etexilate—Angiopathy—Methotrexate—systemic lupus erythematosus	7.09e-05	0.000923	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—systemic lupus erythematosus	7.06e-05	0.000919	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	7.05e-05	0.000919	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	7.04e-05	0.000917	CcSEcCtD
Dabigatran etexilate—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	7.03e-05	0.000916	CcSEcCtD
Dabigatran etexilate—Hypertension—Prednisone—systemic lupus erythematosus	7.02e-05	0.000915	CcSEcCtD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—systemic lupus erythematosus	6.99e-05	0.00275	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	6.95e-05	0.000905	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	6.95e-05	0.000905	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—systemic lupus erythematosus	6.94e-05	0.00273	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	6.93e-05	0.000903	CcSEcCtD
Dabigatran etexilate—Arthralgia—Prednisone—systemic lupus erythematosus	6.93e-05	0.000903	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	6.93e-05	0.00272	CbGpPWpGaD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	6.88e-05	0.000896	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Cyclosporine—systemic lupus erythematosus	6.87e-05	0.000895	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	6.86e-05	0.000893	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—RASGRP1—systemic lupus erythematosus	6.83e-05	0.00269	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—TNF—systemic lupus erythematosus	6.83e-05	0.00269	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IFNG—systemic lupus erythematosus	6.82e-05	0.00268	CbGpPWpGaD
Dabigatran etexilate—Malnutrition—Methotrexate—systemic lupus erythematosus	6.8e-05	0.000886	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Prednisolone—systemic lupus erythematosus	6.73e-05	0.000877	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Betamethasone—systemic lupus erythematosus	6.71e-05	0.000875	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Dexamethasone—systemic lupus erythematosus	6.71e-05	0.000875	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	6.7e-05	0.000873	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CXCL12—systemic lupus erythematosus	6.7e-05	0.00263	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Triamcinolone—systemic lupus erythematosus	6.68e-05	0.00087	CcSEcCtD
Dabigatran etexilate—Urticaria—Methylprednisolone—systemic lupus erythematosus	6.66e-05	0.000868	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—RXRA—systemic lupus erythematosus	6.66e-05	0.00262	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Cyclosporine—systemic lupus erythematosus	6.64e-05	0.000865	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Prednisone—systemic lupus erythematosus	6.64e-05	0.000865	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	6.63e-05	0.000864	CcSEcCtD
Dabigatran etexilate—Infection—Prednisone—systemic lupus erythematosus	6.6e-05	0.00086	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	6.58e-05	0.000858	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	6.58e-05	0.000858	CcSEcCtD
Dabigatran etexilate—Back pain—Methotrexate—systemic lupus erythematosus	6.58e-05	0.000857	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	6.58e-05	0.000857	CcSEcCtD
Dabigatran etexilate—Fatigue—Dexamethasone—systemic lupus erythematosus	6.57e-05	0.000857	CcSEcCtD
Dabigatran etexilate—Fatigue—Betamethasone—systemic lupus erythematosus	6.57e-05	0.000857	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—PTGS2—systemic lupus erythematosus	6.54e-05	0.00257	CbGpPWpGaD
Dabigatran etexilate—Shock—Prednisone—systemic lupus erythematosus	6.53e-05	0.000851	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Prednisone—systemic lupus erythematosus	6.51e-05	0.000849	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—ITGAX—systemic lupus erythematosus	6.5e-05	0.00256	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	6.48e-05	0.000844	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL17A—systemic lupus erythematosus	6.47e-05	0.00254	CbGpPWpGaD
Dabigatran etexilate—Skin disorder—Prednisone—systemic lupus erythematosus	6.45e-05	0.00084	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—F3—systemic lupus erythematosus	6.41e-05	0.00252	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Hydrocortisone—systemic lupus erythematosus	6.4e-05	0.000834	CcSEcCtD
Dabigatran etexilate—Vomiting—Cyclosporine—systemic lupus erythematosus	6.38e-05	0.000832	CcSEcCtD
Dabigatran etexilate—Rash—Cyclosporine—systemic lupus erythematosus	6.33e-05	0.000825	CcSEcCtD
Dabigatran etexilate—Dermatitis—Cyclosporine—systemic lupus erythematosus	6.33e-05	0.000824	CcSEcCtD
Dabigatran etexilate—Pruritus—Hydrocortisone—systemic lupus erythematosus	6.31e-05	0.000823	CcSEcCtD
Dabigatran etexilate—Headache—Cyclosporine—systemic lupus erythematosus	6.29e-05	0.00082	CcSEcCtD
Dabigatran etexilate—Anaemia—Methotrexate—systemic lupus erythematosus	6.28e-05	0.000819	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—P2RY12—systemic lupus erythematosus	6.28e-05	0.00247	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	6.23e-05	0.000812	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	6.23e-05	0.000812	CcSEcCtD
Dabigatran etexilate—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	6.23e-05	0.000812	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	6.19e-05	0.000807	CcSEcCtD
Dabigatran etexilate—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	6.18e-05	0.00243	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	6.18e-05	0.000805	CcSEcCtD
Dabigatran etexilate—Rash—Mycophenolate mofetil—systemic lupus erythematosus	6.18e-05	0.000805	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	6.17e-05	0.000804	CcSEcCtD
Dabigatran etexilate—Headache—Mycophenolate mofetil—systemic lupus erythematosus	6.14e-05	0.0008	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	6.11e-05	0.000796	CcSEcCtD
Dabigatran etexilate—Urticaria—Betamethasone—systemic lupus erythematosus	6.06e-05	0.000789	CcSEcCtD
Dabigatran etexilate—Urticaria—Dexamethasone—systemic lupus erythematosus	6.06e-05	0.000789	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	6.05e-05	0.000788	CcSEcCtD
Dabigatran etexilate—Dizziness—Prednisolone—systemic lupus erythematosus	6.04e-05	0.000787	CcSEcCtD
Dabigatran etexilate—Asthenia—Triamcinolone—systemic lupus erythematosus	6.03e-05	0.000786	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dexamethasone—systemic lupus erythematosus	6.03e-05	0.000785	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Betamethasone—systemic lupus erythematosus	6.03e-05	0.000785	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	6.02e-05	0.00237	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Methylprednisolone—systemic lupus erythematosus	6.02e-05	0.000784	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—MAN2A1—systemic lupus erythematosus	6.02e-05	0.00237	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL12B—systemic lupus erythematosus	6.01e-05	0.00236	CbGpPWpGaD
Dabigatran etexilate—Nausea—Cyclosporine—systemic lupus erythematosus	5.96e-05	0.000777	CcSEcCtD
Dabigatran etexilate—Pruritus—Triamcinolone—systemic lupus erythematosus	5.95e-05	0.000775	CcSEcCtD
Dabigatran etexilate—Cough—Methotrexate—systemic lupus erythematosus	5.93e-05	0.000773	CcSEcCtD
Dabigatran etexilate—Pruritus—Methylprednisolone—systemic lupus erythematosus	5.93e-05	0.000773	CcSEcCtD
Dabigatran etexilate—Dizziness—Hydrocortisone—systemic lupus erythematosus	5.9e-05	0.000769	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Prednisone—systemic lupus erythematosus	5.85e-05	0.000762	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—RXRA—systemic lupus erythematosus	5.84e-05	0.0023	CbGpPWpGaD
Dabigatran etexilate—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	5.82e-05	0.000758	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—CXCL12—systemic lupus erythematosus	5.8e-05	0.00228	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—CLU—systemic lupus erythematosus	5.8e-05	0.00228	CbGpPWpGaD
Dabigatran etexilate—Chest pain—Methotrexate—systemic lupus erythematosus	5.79e-05	0.000754	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—systemic lupus erythematosus	5.79e-05	0.000754	CcSEcCtD
Dabigatran etexilate—Rash—Prednisolone—systemic lupus erythematosus	5.76e-05	0.000751	CcSEcCtD
Dabigatran etexilate—Dermatitis—Prednisolone—systemic lupus erythematosus	5.76e-05	0.00075	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	5.75e-05	0.000749	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	5.74e-05	0.000748	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD40—systemic lupus erythematosus	5.74e-05	0.00226	CbGpPWpGaD
Dabigatran etexilate—Fatigue—Prednisone—systemic lupus erythematosus	5.72e-05	0.000746	CcSEcCtD
Dabigatran etexilate—Headache—Prednisolone—systemic lupus erythematosus	5.72e-05	0.000746	CcSEcCtD
Dabigatran etexilate—Constipation—Prednisone—systemic lupus erythematosus	5.68e-05	0.00074	CcSEcCtD
Dabigatran etexilate—Vomiting—Hydrocortisone—systemic lupus erythematosus	5.67e-05	0.000739	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCR5—systemic lupus erythematosus	5.67e-05	0.00223	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CTLA4—systemic lupus erythematosus	5.65e-05	0.00222	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—systemic lupus erythematosus	5.63e-05	0.00221	CbGpPWpGaD
Dabigatran etexilate—Rash—Hydrocortisone—systemic lupus erythematosus	5.63e-05	0.000733	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	5.62e-05	0.00221	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Hydrocortisone—systemic lupus erythematosus	5.62e-05	0.000733	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—P2RY12—systemic lupus erythematosus	5.61e-05	0.00221	CbGpPWpGaD
Dabigatran etexilate—Headache—Hydrocortisone—systemic lupus erythematosus	5.59e-05	0.000729	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—TNF—systemic lupus erythematosus	5.56e-05	0.00219	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Triamcinolone—systemic lupus erythematosus	5.56e-05	0.000724	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—systemic lupus erythematosus	5.55e-05	0.000723	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCL12—systemic lupus erythematosus	5.55e-05	0.00218	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Methylprednisolone—systemic lupus erythematosus	5.54e-05	0.000723	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—C3—systemic lupus erythematosus	5.54e-05	0.00218	CbGpPWpGaD
Dabigatran etexilate—Infection—Methotrexate—systemic lupus erythematosus	5.51e-05	0.000718	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IL6—systemic lupus erythematosus	5.51e-05	0.00217	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Dexamethasone—systemic lupus erythematosus	5.47e-05	0.000713	CcSEcCtD
Dabigatran etexilate—Asthenia—Betamethasone—systemic lupus erythematosus	5.47e-05	0.000713	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methotrexate—systemic lupus erythematosus	5.44e-05	0.000709	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	5.43e-05	0.000708	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	5.43e-05	0.000708	CcSEcCtD
Dabigatran etexilate—Nausea—Prednisolone—systemic lupus erythematosus	5.43e-05	0.000707	CcSEcCtD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—JAK1—systemic lupus erythematosus	5.42e-05	0.00213	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Betamethasone—systemic lupus erythematosus	5.39e-05	0.000703	CcSEcCtD
Dabigatran etexilate—Pruritus—Dexamethasone—systemic lupus erythematosus	5.39e-05	0.000703	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methotrexate—systemic lupus erythematosus	5.39e-05	0.000702	CcSEcCtD
Dabigatran etexilate—Vomiting—Triamcinolone—systemic lupus erythematosus	5.34e-05	0.000696	CcSEcCtD
Dabigatran etexilate—Vomiting—Methylprednisolone—systemic lupus erythematosus	5.33e-05	0.000695	CcSEcCtD
Dabigatran etexilate—Nausea—Hydrocortisone—systemic lupus erythematosus	5.3e-05	0.000691	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—JAK1—systemic lupus erythematosus	5.3e-05	0.00208	CbGpPWpGaD
Dabigatran etexilate—Rash—Triamcinolone—systemic lupus erythematosus	5.3e-05	0.00069	CcSEcCtD
Dabigatran etexilate—Dermatitis—Triamcinolone—systemic lupus erythematosus	5.29e-05	0.00069	CcSEcCtD
Dabigatran etexilate—Rash—Methylprednisolone—systemic lupus erythematosus	5.29e-05	0.000689	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methylprednisolone—systemic lupus erythematosus	5.28e-05	0.000688	CcSEcCtD
Dabigatran etexilate—Urticaria—Prednisone—systemic lupus erythematosus	5.28e-05	0.000687	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—PPARG—systemic lupus erythematosus	5.27e-05	0.00207	CbGpPWpGaD
Dabigatran etexilate—Headache—Triamcinolone—systemic lupus erythematosus	5.26e-05	0.000686	CcSEcCtD
Dabigatran etexilate—Headache—Methylprednisolone—systemic lupus erythematosus	5.25e-05	0.000684	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Prednisone—systemic lupus erythematosus	5.25e-05	0.000684	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Betamethasone—systemic lupus erythematosus	5.22e-05	0.00068	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dexamethasone—systemic lupus erythematosus	5.22e-05	0.00068	CcSEcCtD
Dabigatran etexilate—Hypotension—Methotrexate—systemic lupus erythematosus	5.19e-05	0.000676	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—CSK—systemic lupus erythematosus	5.17e-05	0.00203	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SELE—systemic lupus erythematosus	5.17e-05	0.00203	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—systemic lupus erythematosus	5.16e-05	0.00203	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—TGFB1—systemic lupus erythematosus	5.12e-05	0.00201	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	5.06e-05	0.000659	CcSEcCtD
Dabigatran etexilate—Dizziness—Betamethasone—systemic lupus erythematosus	5.04e-05	0.000657	CcSEcCtD
Dabigatran etexilate—Dizziness—Dexamethasone—systemic lupus erythematosus	5.04e-05	0.000657	CcSEcCtD
Dabigatran etexilate—Nausea—Triamcinolone—systemic lupus erythematosus	4.99e-05	0.00065	CcSEcCtD
Dabigatran etexilate—Nausea—Methylprednisolone—systemic lupus erythematosus	4.98e-05	0.000649	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DQA1—systemic lupus erythematosus	4.98e-05	0.00196	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2RA—systemic lupus erythematosus	4.95e-05	0.00195	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Methotrexate—systemic lupus erythematosus	4.95e-05	0.000645	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Prednisone—systemic lupus erythematosus	4.89e-05	0.000638	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methotrexate—systemic lupus erythematosus	4.88e-05	0.000637	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—ITGAM—systemic lupus erythematosus	4.86e-05	0.00191	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Dexamethasone—systemic lupus erythematosus	4.85e-05	0.000632	CcSEcCtD
Dabigatran etexilate—Vomiting—Betamethasone—systemic lupus erythematosus	4.85e-05	0.000632	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—NAT2—systemic lupus erythematosus	4.81e-05	0.00189	CbGpPWpGaD
Dabigatran etexilate—Rash—Betamethasone—systemic lupus erythematosus	4.81e-05	0.000626	CcSEcCtD
Dabigatran etexilate—Rash—Dexamethasone—systemic lupus erythematosus	4.81e-05	0.000626	CcSEcCtD
Dabigatran etexilate—Dermatitis—Betamethasone—systemic lupus erythematosus	4.8e-05	0.000626	CcSEcCtD
Dabigatran etexilate—Dermatitis—Dexamethasone—systemic lupus erythematosus	4.8e-05	0.000626	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	4.79e-05	0.000624	CcSEcCtD
Dabigatran etexilate—Fatigue—Methotrexate—systemic lupus erythematosus	4.78e-05	0.000623	CcSEcCtD
Dabigatran etexilate—Headache—Betamethasone—systemic lupus erythematosus	4.78e-05	0.000622	CcSEcCtD
Dabigatran etexilate—Headache—Dexamethasone—systemic lupus erythematosus	4.78e-05	0.000622	CcSEcCtD
Dabigatran etexilate—Asthenia—Prednisone—systemic lupus erythematosus	4.76e-05	0.000621	CcSEcCtD
Dabigatran etexilate—Pruritus—Prednisone—systemic lupus erythematosus	4.7e-05	0.000612	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—LYN—systemic lupus erythematosus	4.69e-05	0.00185	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DQB1—systemic lupus erythematosus	4.66e-05	0.00183	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SH2B3—systemic lupus erythematosus	4.6e-05	0.00181	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Prednisone—systemic lupus erythematosus	4.54e-05	0.000592	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	4.54e-05	0.000591	CcSEcCtD
Dabigatran etexilate—Nausea—Betamethasone—systemic lupus erythematosus	4.53e-05	0.00059	CcSEcCtD
Dabigatran etexilate—Nausea—Dexamethasone—systemic lupus erythematosus	4.53e-05	0.00059	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—IL6—systemic lupus erythematosus	4.48e-05	0.00176	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—TNF—systemic lupus erythematosus	4.41e-05	0.00174	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Methotrexate—systemic lupus erythematosus	4.41e-05	0.000574	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD40LG—systemic lupus erythematosus	4.4e-05	0.00173	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL10—systemic lupus erythematosus	4.4e-05	0.00173	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Prednisone—systemic lupus erythematosus	4.39e-05	0.000572	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—systemic lupus erythematosus	4.39e-05	0.000572	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL2—systemic lupus erythematosus	4.33e-05	0.0017	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL4—systemic lupus erythematosus	4.28e-05	0.00168	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL12—systemic lupus erythematosus	4.22e-05	0.00166	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Prednisone—systemic lupus erythematosus	4.22e-05	0.00055	CcSEcCtD
Dabigatran etexilate—Rash—Prednisone—systemic lupus erythematosus	4.19e-05	0.000546	CcSEcCtD
Dabigatran etexilate—Dermatitis—Prednisone—systemic lupus erythematosus	4.18e-05	0.000545	CcSEcCtD
Dabigatran etexilate—Headache—Prednisone—systemic lupus erythematosus	4.16e-05	0.000542	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Methotrexate—systemic lupus erythematosus	4.09e-05	0.000533	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—FASLG—systemic lupus erythematosus	4.09e-05	0.00161	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Methotrexate—systemic lupus erythematosus	3.98e-05	0.000519	CcSEcCtD
Dabigatran etexilate—Nausea—Prednisone—systemic lupus erythematosus	3.94e-05	0.000514	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—FAS—systemic lupus erythematosus	3.94e-05	0.00155	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Methotrexate—systemic lupus erythematosus	3.93e-05	0.000512	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2RA—systemic lupus erythematosus	3.92e-05	0.00154	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—C3—systemic lupus erythematosus	3.89e-05	0.00153	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	3.84e-05	0.00151	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCR5—systemic lupus erythematosus	3.8e-05	0.00149	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Methotrexate—systemic lupus erythematosus	3.8e-05	0.000495	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—C3—systemic lupus erythematosus	3.71e-05	0.00146	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Methotrexate—systemic lupus erythematosus	3.67e-05	0.000478	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—IFNA1—systemic lupus erythematosus	3.62e-05	0.00142	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—ALB—systemic lupus erythematosus	3.58e-05	0.00141	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—systemic lupus erythematosus	3.56e-05	0.0014	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	3.56e-05	0.0014	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—systemic lupus erythematosus	3.55e-05	0.0014	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—P2RY12—systemic lupus erythematosus	3.55e-05	0.00139	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—HLA-DRB1—systemic lupus erythematosus	3.54e-05	0.00139	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Methotrexate—systemic lupus erythematosus	3.53e-05	0.00046	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—RASGRP1—systemic lupus erythematosus	3.52e-05	0.00139	CbGpPWpGaD
Dabigatran etexilate—Rash—Methotrexate—systemic lupus erythematosus	3.5e-05	0.000456	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—systemic lupus erythematosus	3.5e-05	0.000456	CcSEcCtD
Dabigatran etexilate—Headache—Methotrexate—systemic lupus erythematosus	3.48e-05	0.000453	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—EP300—systemic lupus erythematosus	3.45e-05	0.00136	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—systemic lupus erythematosus	3.44e-05	0.00135	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—systemic lupus erythematosus	3.37e-05	0.00133	CbGpPWpGaD
Dabigatran etexilate—Nausea—Methotrexate—systemic lupus erythematosus	3.3e-05	0.00043	CcSEcCtD
Dabigatran etexilate—ABCB1—Allograft Rejection—CD80—systemic lupus erythematosus	3.27e-05	0.00129	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—P2RY12—systemic lupus erythematosus	3.22e-05	0.00127	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—ACE—systemic lupus erythematosus	2.98e-05	0.00117	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	2.98e-05	0.00117	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—TGFB1—systemic lupus erythematosus	2.94e-05	0.00116	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic lupus erythematosus	2.91e-05	0.00114	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2—systemic lupus erythematosus	2.9e-05	0.00114	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCR5—systemic lupus erythematosus	2.89e-05	0.00114	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—C3—systemic lupus erythematosus	2.83e-05	0.00111	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	2.81e-05	0.0011	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—JAK1—systemic lupus erythematosus	2.73e-05	0.00107	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—RXRA—systemic lupus erythematosus	2.7e-05	0.00106	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IFNG—systemic lupus erythematosus	2.59e-05	0.00102	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2RA—systemic lupus erythematosus	2.55e-05	0.001	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—systemic lupus erythematosus	2.47e-05	0.00097	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	2.46e-05	0.000968	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TGFB1—systemic lupus erythematosus	2.39e-05	0.00094	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL12—systemic lupus erythematosus	2.39e-05	0.000939	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EP300—systemic lupus erythematosus	2.38e-05	0.000936	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—systemic lupus erythematosus	2.33e-05	0.000914	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—systemic lupus erythematosus	2.3e-05	0.000903	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TGFB1—systemic lupus erythematosus	2.26e-05	0.00089	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—systemic lupus erythematosus	2.25e-05	0.000886	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	2.24e-05	0.000881	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—RASGRP1—systemic lupus erythematosus	2.23e-05	0.000875	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL2—systemic lupus erythematosus	2.21e-05	0.00087	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NAT2—systemic lupus erythematosus	2.19e-05	0.000862	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL12—systemic lupus erythematosus	2.17e-05	0.000852	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—RASGRP1—systemic lupus erythematosus	2.02e-05	0.000795	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	2.02e-05	0.000793	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TLR9—systemic lupus erythematosus	1.96e-05	0.000773	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—systemic lupus erythematosus	1.95e-05	0.000768	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	1.94e-05	0.000765	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—P2RY12—systemic lupus erythematosus	1.9e-05	0.000748	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ALB—systemic lupus erythematosus	1.84e-05	0.000725	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	1.8e-05	0.000707	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TGFB1—systemic lupus erythematosus	1.79e-05	0.000705	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NAT2—systemic lupus erythematosus	1.78e-05	0.0007	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NOS3—systemic lupus erythematosus	1.76e-05	0.000694	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CSK—systemic lupus erythematosus	1.75e-05	0.000689	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—systemic lupus erythematosus	1.74e-05	0.000686	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—JAK1—systemic lupus erythematosus	1.73e-05	0.000679	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARG—systemic lupus erythematosus	1.7e-05	0.00067	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—systemic lupus erythematosus	1.67e-05	0.000658	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CCR5—systemic lupus erythematosus	1.64e-05	0.000643	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2RA—systemic lupus erythematosus	1.61e-05	0.000634	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NCF2—systemic lupus erythematosus	1.6e-05	0.00063	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—C3—systemic lupus erythematosus	1.6e-05	0.000629	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LYN—systemic lupus erythematosus	1.59e-05	0.000626	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—JAK1—systemic lupus erythematosus	1.57e-05	0.000616	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SH2B3—systemic lupus erythematosus	1.56e-05	0.000614	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CCL2—systemic lupus erythematosus	1.56e-05	0.000612	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALB—systemic lupus erythematosus	1.53e-05	0.000602	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—systemic lupus erythematosus	1.5e-05	0.000588	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCR5—systemic lupus erythematosus	1.49e-05	0.000584	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—NOS3—systemic lupus erythematosus	1.46e-05	0.000576	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2RA—systemic lupus erythematosus	1.46e-05	0.000576	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—C3—systemic lupus erythematosus	1.45e-05	0.000571	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.42e-05	0.000557	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—EP300—systemic lupus erythematosus	1.34e-05	0.000528	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—systemic lupus erythematosus	1.34e-05	0.000527	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL12—systemic lupus erythematosus	1.28e-05	0.000504	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.27e-05	0.0005	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—systemic lupus erythematosus	1.27e-05	0.0005	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JUNB—systemic lupus erythematosus	1.26e-05	0.000494	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—RXRA—systemic lupus erythematosus	1.23e-05	0.000483	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—systemic lupus erythematosus	1.22e-05	0.000481	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RASGRP1—systemic lupus erythematosus	1.19e-05	0.00047	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—systemic lupus erythematosus	1.17e-05	0.000459	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	1.16e-05	0.000456	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PRL—systemic lupus erythematosus	1.16e-05	0.000455	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL2—systemic lupus erythematosus	1.14e-05	0.000447	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—EP300—systemic lupus erythematosus	1.11e-05	0.000438	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.11e-05	0.000438	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	1.07e-05	0.00042	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—TYK2—systemic lupus erythematosus	1.03e-05	0.000406	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	1.02e-05	0.0004	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—RXRA—systemic lupus erythematosus	9.98e-06	0.000393	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	9.78e-06	0.000384	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	9.63e-06	0.000379	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—systemic lupus erythematosus	9.45e-06	0.000372	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JAK1—systemic lupus erythematosus	9.26e-06	0.000364	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	9.26e-06	0.000364	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	8.84e-06	0.000348	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCR5—systemic lupus erythematosus	8.78e-06	0.000345	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2RA—systemic lupus erythematosus	8.65e-06	0.00034	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—systemic lupus erythematosus	8.58e-06	0.000338	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—C3—systemic lupus erythematosus	8.58e-06	0.000337	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	8.26e-06	0.000325	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NAT2—systemic lupus erythematosus	8.17e-06	0.000321	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARG—systemic lupus erythematosus	7.76e-06	0.000305	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD80—systemic lupus erythematosus	7.22e-06	0.000284	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—systemic lupus erythematosus	6.97e-06	0.000274	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL2—systemic lupus erythematosus	6.71e-06	0.000264	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NOS3—systemic lupus erythematosus	6.67e-06	0.000262	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARG—systemic lupus erythematosus	6.3e-06	0.000248	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—systemic lupus erythematosus	6.1e-06	0.00024	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TYK2—systemic lupus erythematosus	6.09e-06	0.00024	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOS3—systemic lupus erythematosus	5.98e-06	0.000235	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—systemic lupus erythematosus	5.67e-06	0.000223	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	5.55e-06	0.000218	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NOS3—systemic lupus erythematosus	5.42e-06	0.000213	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—systemic lupus erythematosus	5.18e-06	0.000204	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—EP300—systemic lupus erythematosus	5.07e-06	0.0002	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—systemic lupus erythematosus	5.07e-06	0.000199	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—systemic lupus erythematosus	5.05e-06	0.000198	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—systemic lupus erythematosus	4.96e-06	0.000195	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—systemic lupus erythematosus	4.8e-06	0.000189	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—systemic lupus erythematosus	4.78e-06	0.000188	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	4.58e-06	0.00018	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EP300—systemic lupus erythematosus	4.55e-06	0.000179	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—systemic lupus erythematosus	4.31e-06	0.000169	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—EP300—systemic lupus erythematosus	4.12e-06	0.000162	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—systemic lupus erythematosus	3.96e-06	0.000156	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—systemic lupus erythematosus	2.98e-06	0.000117	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	2.89e-06	0.000114	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—systemic lupus erythematosus	2.6e-06	0.000102	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	2.49e-06	9.78e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	2.27e-06	8.94e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EP300—systemic lupus erythematosus	1.89e-06	7.44e-05	CbGpPWpGaD
